Erratum: A Novel Triterpenoid Isolated from the Root Bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a Potential AntiCancer Agent(PLoS ONE (2019) 4:4 (e5365) DOI: 10.1371/journal.pone.0005365);A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Lavhale, Manish S ^a   Kumar, Santosh ^b   Mishra, Shri Hari ^a   Sitasawad, Sandhya L ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AILANTHUS EXCELSA CHLOROFORM EXTRACT 1; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; MYC PROTEIN; PACLITAXEL; PLANT EXTRACT; PROTEIN P21; PROTEIN P53; SERINE; TRITERPENOID; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; TRITERPENE; TUMOR SUPPRESSOR PROTEIN;

AILANTHUS; AILANTHUS EXCELSA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARK; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PLANT ROOT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOLID TUMOR; TUMOR VOLUME; ANIMAL; BREAST TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MELANOMA; ISOLATION AND PURIFICATION; MEDICINAL PLANT; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

AILANTHUS; AILANTHUS ALTISSIMA; MUS; MUS MUSCULUS;

AILANTHUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; PACLITAXEL; PLANTS, MEDICINAL; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES; TUMOR SUPPRESSOR PROTEINS;

EID: 65449183737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0231249     Document Type: Erratum

References (32)

1. American Cancer Society (2002) Cancer Facts & Figures.
2. Ferlay J, Bray F, Parkin DM, Pisani P, eds (2001) Globocan 2000: Cancer Incidence and Mortality Worldwide. IARC Cancer Bases No. 5. Lyon: IARCPress.
3. Cragg GM, Newman DJ (2004) Plants as a source of anti-cancer agents. In: Elisabetsky E, Etkin NL, eds. Ethnopharmacology. In Encyclopedia of Life Support Systems (EOLSS). Developed under the Auspices of the UNESCO. Oxford, UK: Eolss Publishers.
4. Philip PA (2005) Experience with docetaxel in the treatment of gastric cancer. Semin Oncol 32: 24-38.
5. Chung KT, Wong TY, Wei CI, Huang YW, Lin Y (1998) Tannins and human health: a review. Crit Rev Food Sci Nutr 38: 421-424.
6. Ronconi L, Giovagnini L, Marzano C, Bettio F, Graziani R, et al. (2005) Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties and in vitro antitumor activity. Inorg Chem 44: 1867-1881.
7. Alderden RA, Hall MD, Hambley TW (2006) The discovery and development of cisplatin. J Chem Ed 83: 728-734.
8. Tang W, Hemm I, Bertram B (2003) Recent development of antitumor agents from Chinese herbal medicines; Part I. Low molecular compounds. Planta Med 69: 97-108.
9. Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, et al. (2006) Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 23: 394-411.
10. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, et al. (1998) Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 8: 2711-2714.
11. Honda T, Honda Y, Favaloro FG Jr, Gribble GW, Suh N, et al. (2002) A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 12: 1027-1030.
12. Kirtikar KR, Basu BD In: Indian Medicinal Plants. Dehradun, India: International Books Distributor 1: 505-507.
13. Honda T, Imao K, Nakatsuka N, Nakanishi T (1987) Novel Ailanthone Derivatives and Production Process Thereof. United States Patent No. 4665201.
14. Ogura M, Cordell GA, Fransworth NR (1978) Alkaloid constituents of A. excelsa. Lloydia 41: 166.
15. Lasek W, Wankowicz A, Kuc K, Feleszko W, Golab J, et al. (1995) Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in an MmB16 melanoma model in mice. Cancer Immunol Immunother 40: 315-321.
16. Pallavicini MG, Gray JW, Darzynkiewicz Z, eds (1987) Techniques in Cell Cycle Analysis. Clifton, NJ: Humana Press 139-162.
17. Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA, et al. (2002) Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res 62: 1439-1442.
18. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, et al. (2001) Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 61: 4229-4237.
19. Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, et al. (2006) The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res 66: 951-959.
20. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, et al. (2002) Distinct and complementary information provided by use of tissue and cDNA microarrays in the study of breast tumor markers. Am J Pathol 161: 1223-1233.
21. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53.
22. Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58: 4023-4037.
23. Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4: 70-76.
24. Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, et al. (2008) TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene 27: 116-125.
25. Stewart ZA, Tang LJ, Pietenpol JA (2001) Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20: 113-124.
26. Shouse GP, Cai X, Liu X (2008) Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol 28: 448-456.
27. Baruah H, Barry CG, Bierbach U (2004) Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. Curr Top Med Chem 4: 1537-1549.
28. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) P21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
29. Yim D, Singh RP, Agarwal C, Lee S, Chi H, et al. (2005) A novel anti-cancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res 65: 1035-1144.
30. Bishop JM (1983) Cellular oncogene and retroviruses. Annu Rev Biochem 52: 301-354.
31. Karn J, Watson JV, Lowe AD, Green SM, Vedeckis W (1989) Regulation of cell cycle duration by c-myc levels. Oncogene 4: 773-787.
32. Mateyak MK, Obaya AJ, Sedivy JM (1999) c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 19: 4672-4683.